Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Aldeyra Looking At Paths To Approval In Dry Eye After Phase III Miss

Dec 22 2021

• By Joseph Haas

Blue eye detail — Aldeyra puts dry eye hopes on revised Phase III protocol

Related Content

In Dry Eye, A Variety Of Mechanisms Pursue Established Therapies

Jan 15 2018

Ocular’s OTX-DED Succeeds In Dry Eye Where OTX-CSI Failed, But More Data Needed

Dec 06 2021

Aldeyra Allergic Conjunctivitis Drug Has Good Prospects With Phase III Results

Apr 27 2021

Aerie Misses Quick Path To Dry Eye Approval, But Is Still Moving Forward

Sep 16 2021

Ocular’s Dry Eye Drug Fails In Phase II, But It Isn’t Giving Up Yet

Oct 22 2021

Related Companies

Aldeyra Therapeutics, Inc.

Aerie Pharmaceuticals, Inc.

Novartis AG

Additional Topics

Clinical Trials Drug Approval Standards Business Strategies Research & Development Ophthalmic BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window